Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment - Footnotes (Details) - USD ($) $ in Millions		3 Months Ended			6 Months Ended
		Jun. 30, 2024	Mar. 31, 2024	Jul. 02, 2023	Jun. 30, 2024	Jul. 02, 2023
Segment Reporting Information [Line Items]
Income from continuing operations before provision/(benefit) for taxes on income (loss)	[1]	$ 103		$ (2,269)	$ (3,318)	$ (8,539)
Restructuring charges and certain acquisition-related costs		1,254		214	1,356	222
ViiV [Member]
Segment Reporting Information [Line Items]
Dividend income					(135)	(183)
Biopharma [Member] | ViiV [Member]
Segment Reporting Information [Line Items]
Dividend income		(74)		(91)	(135)	(183)
Paxlovid [Member]
Segment Reporting Information [Line Items]
Favorable adjustment for government emergency use authorization inventory returned to the company during the period			$ 771		771
Paxlovid [Member] | Biopharma [Member]
Segment Reporting Information [Line Items]
Favorable adjustment for government emergency use authorization inventory returned to the company during the period		771			771
Other Business Activities [Member]
Segment Reporting Information [Line Items]
Income from continuing operations before provision/(benefit) for taxes on income (loss)	[1],[2]	1,985		910	3,992	2,225
Reconciling Items [Member] | Certain Significant Items [Member]
Segment Reporting Information [Line Items]
Income from continuing operations before provision/(benefit) for taxes on income (loss)	[1],[3]	2,091		$ 293	2,469	$ 958
Restructuring charges and certain acquisition-related costs		1,200			1,200
Reclassification Other [Member] | Other Business Activities [Member]
Segment Reporting Information [Line Items]
Income from continuing operations before provision/(benefit) for taxes on income (loss)		$ (2,000)			$ (3,400)

[1] Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss). As described above, in connection with the organizational changes effective in the first quarter of 2024, costs associated with R&D and medical and safety activities managed by our global ORD and PRD organizations and overhead costs associated with our manufacturing operations are now included in Biopharma’s earnings. We have reclassified $2.0 billion and $3.4 billion of net costs in the second quarter and first six months of 2023, respectively, from Other business activities to Biopharma to conform to the current period presentation.

[2] Other business activities include revenues and costs associated with PC1 and Pfizer Ignite as well as costs that we do not allocate to our operating segments, per above.

[3] Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above). Earnings in the second quarter and first six months of 2024 includes, among other items, restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $1.2 billion (primarily recorded in Restructuring charges and certain acquisition-related costs). See Note 3.